Abstract:Immunotherapy with anti-programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) monoclonal antibodies has become routine in the treatment of many kinds of human cancers, such as lung cancer, intestinal cancer, and melanoma. The PD-1/PD-L1 pathway inhibits T cell activation in the micro-environment, making it an attractive target against cancer. Wild-type (WT) PD-1 ectodomain has been shown to have difficulty blocking PD-1/PD-L1 mixture formation due to its low affinity. The present work uses three-dimensional (3D) crystal complex structures to analyze the interaction by which PD-1 binds to PD-Ll or PD-L2. It also reports on a theoretical study of the binding mode between PD-1 and its clinical antibody Opdivo. Based on the theoretical binding analysis of PD-1 and its ligands (i.e., PD-Ll and PD-L2) or antibody (Opdivo), a small-content, epitope-oriented mammalian cell library was established for PD-1. After three rounds of cell sorting, the decoy PD-1 mutant 463, which presented a higher affinity than WT PD-1 to the PD-Ll (the affinity has increased by almost three orders of magnitude) was screened out. It exhibited an inhibitory effect against PD-1 to prevent it from forming mixtures with PD-L1, which was similar to the effect of the commercial anti-PD-Ll antibody atezolizumab (ATE). The median effective concentration (EC50) value of the decoy mutant was 0.031 mu g.mL(-1) in comparison with 0.063 mu g.mL(-1) for ATE; both values were much lower than that of WT PD-1, at 2.571 mu g.mL(-)(1) . The 463 decoy mutant reversed the inhibitory function of PD-1 in T cell activation; furthermore, 10 mg.kg(-1) of 463 inhibited about 75% of tumor growth in vivo in a MC38 transgenic xenograft mice model, which was similar to the activity of ATE. More interestingly, an even lower dose of 463 (2 mg.kg(-1)) showed a better effect than 10 mg.kg(-1) of WT PD-1. This work offers the decoy 463 with an improved curative effect, which holds potential to become a good option against PD-1/PD-L1-related cancers. (C) 2021 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company.

Miniprotein engineering for inhibition of PD‐1/PD‐L1 interaction

Design of a protease‐activated PD‐L1 inhibitor

Rational Development of Molecularly Imprinted Nanoparticles for Blocking PD-1/PD-L1 Axis

Discovery of Peptide Inhibitors Targeting Human Programmed Death 1 (PD-1) Receptor.

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction

In silico evolution of autoinhibitory domains for a PD-L1 antagonist using deep learning models

Engineering a High-Affinity PD-1 Peptide for Optimized Immune Cell-Mediated Tumor Therapy

Synthesis and preliminary evaluation of aminophenol derivatives as molecular glues blocking PD-1/PD-L1 interaction

A Platform of ADAPTive Scaffolds: Development of CDR-H3 -Hairpin Mimics into Covalent Inhibitors of the PD1/PDL1 Immune Checkpoint.

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy

High-Affinity Decoy PD-1 Mutant Screened from an Epitope-Specific Cell Library

A Peptidic Inhibitor for PD-1 Palmitoylation Targets Its Expression and Functions.

Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles

Structure-Guided Discovery of PD-1/PD-L1 Interaction Inhibitors: Peptide Design, Screening, and Optimization via Computation-Aided Phage Display Engineering

The design of high affinity human PD-1 mutants by using molecular dynamics simulations (MD)

Inhibition of tumor immune escape by blocking PD-1/PD-L1 engagement with dual-targeting molecularly imprinted polymer layer

Design and Evaluation of Α-Helix-based Peptide Inhibitors for Blocking PD-1/PD-L1 Interaction.

Selective Degradation of PD‐L1 in Cancer Cells by Enzyme‐Instructed Self‐Assembly

Identification of the functional PD-L1 interface region responsible for PD-1 binding and initiation of PD-1 signaling

Discovery of Phenyl-Linked Symmetric Small Molecules As Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.

Peptide Blockers of PD-1-PD-L1 Interaction Reinvigorate PD-1-Suppressed T Cells and Curb Tumor Growth in Mice